- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why | 1 | Benzinga.com | ||
| 04.08. | Mangoceuticals, Inc.: Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination | 109 | GlobeNewswire (Europe) | Dallas, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company") today announced it has received an additional 180-calendar-day extension from... ► Artikel lesen | |
| 03.08. | Nuclea Energy To Go Public Through Mangoceuticals Combination With Former Shareholders Owning About 96% | 2 | pulse2.com | ||
| 30.07. | Nuclea Energy Inc: Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor | 655 | Newsfile | Mississauga, Ontario--(Newsfile Corp. - July 30, 2026) - Nuclea Energy Inc. ("Nuclea" or the "Company"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing... ► Artikel lesen | |
| 30.07. | Mangoceuticals agrees to merge with nuclear microreactor developer | 6 | Investing.com | ||
| 30.07. | Mangoceuticals kündigt Fusion mit Nukleartechnik-Unternehmen Nuclea an | 4 | Investing.com Deutsch | ||
| MANGOCEUTICALS Aktie jetzt für 0€ handeln | |||||
| 30.07. | Mangoceuticals, Inc.: Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology | 6.669 | GlobeNewswire (Europe) | Business Combination Agreement to Bring Nuclea's Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS, July 30, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 30.07. | MANGOCEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 10.07. | MANGOCEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 02.07. | MANGOCEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | MANGOCEUTICALS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 01.04. | MANGOCEUTICALS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | MANGOCEUTICALS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 17.03. | Mangoceuticals verklagt Technologie-Dienstleister auf 73 Millionen US-Dollar | 6 | Investing.com Deutsch | ||
| 17.03. | Mangoceuticals, Inc.: Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. | 425 | GlobeNewswire (Europe) | Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals," the "Company," or "MangoRx"), a company focused on developing, marketing, and selling health... ► Artikel lesen | |
| 17.03. | MANGOCEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 06.03. | Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds | 384 | GlobeNewswire (Europe) | Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine... ► Artikel lesen | |
| 23.02. | Mangoceuticals: Aktie steigt nach positiven Daten zu antiviralem Geflügel-Wirkstoff | 2 | Investing.com Deutsch | ||
| 23.02. | Mangoceuticals, Inc.: Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study | 215 | GlobeNewswire (Europe) | Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine... ► Artikel lesen | |
| 19.02. | MANGOCEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEALWELL AI | 0,439 | -2,66 % | HEALWELL AI kündigt Telefonkonferenz zur Erörterung der Finanzergebnisse des zweiten Quartals 2026 für den 7. August 2026 an | HEALWELL AI wird am Freitag, den 7. August 2026, um 8:30 Uhr ET (5:30 Uhr PT) eine Telefonkonferenz und einen gleichzeitigen Webcast
abhalten
TORONTO, ON, 4. August 2026... ► Artikel lesen | |
| SPINEWAY | 0,116 | +1,75 % | Spineway: H1 2026 results | H1 2026 results Continued growth Stable resultsStrong embedded growth driversIssuance of straight bonds to finance future growth In thousands of eurosConsolidated financial statements - UnauditedH1... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| LIFEWARD | 7,680 | -0,26 % | Lifeward Out With Q2 Numbers | ||
| IMUNON | 1,390 | -0,71 % | Earnings Call: Imunon übertrifft Ergebnisprognose für Q2 2026, doch die Aktie bleibt unter Druck | ||
| INSPIRE MEDICAL SYSTEMS | 52,00 | 0,00 % | Inspire Medical surges on revised guidance, earnings, Street upgrade | ||
| NUWELLIS, INC | 1,490 | +4,93 % | Nuwellis, Inc.: Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer | MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced... ► Artikel lesen | |
| INSPIREMD | 0,620 | +8,77 % | InspireMD Inc.: InspireMD to Announce Second Quarter 2026 Financial Results | ||
| LOGICMARK | - | - | EQS-News: Benzinga: From "Text Me When You Get Home" To Always-On Protection: Themes Emerging Across The Evolution Of LogicMark's Aster | EQS-News: Benzinga
/ Key word(s): Healthcare
From "Text Me When You Get Home" To Always-On Protection: Themes Emerging Across The Evolution Of LogicMark's Aster 19.05.2026 / 15:05... ► Artikel lesen | |
| GT BIOPHARMA | 0,311 | -2,96 % | GT Biopharma, Inc.: GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | GTB-5550 is now the 3rd TriKE- to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation... ► Artikel lesen | |
| MYOMO | 1,190 | -3,57 % | Myomo expects $45M-$47M full-year revenue while targeting second-half cash burn below $2M | ||
| INOGEN | 5,100 | -2,86 % | Inogen Inc - 10-Q, Quarterly Report | ||
| INTELLIGENT BIO SOLUTIONS | 2,050 | +3,54 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission | NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| LEXARIA BIOSCIENCE | 5,580 | +1,64 % | Lexaria Bioscience Corp. - 8-K, Current Report | ||
| GLUCOTRACK | 0,373 | -7,50 % | Glucotrack Secures $5.5 Million Financing Through Equity And Convertible Debt |
MANGOCEUTICALS INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,542 Euro und damit -8,85 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MANGOCEUTICALS INC finden Sie auf Wallstreet Online.